Compare Pfizer Inc (PFE) vs VF Corp (VFC) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

VFC trades at $16.91, down 0.41% with a bearish technical signal. The company shows mixed fundamentals with declining revenue from $11.8B in 2022 to $9.5B in 2025, though recent quarters beat EPS estimates. Net income turned negative in 2025 at -$190M, but 2026 projections show recovery to $255M profit. Valuation metrics appear reasonable with P/E of 26.38 and P/S of 0.7, while analyst consensus targets $19.33 with 43% buy ratings.

VFC faces turnaround challenges with weak Vans performance and consumer headwinds, but improving margins and debt reduction provide catalysts. The stock offers potential upside to analyst targets if brand recovery continues, though execution risks remain elevated given recent volatility and competitive pressures in apparel retail.